Biocon Biologics, a subsidiary of Biocon Ltd, has announced several major executive hires that will play a critical role in modernizing the organization and realizing its aim of becoming a worldwide biosimilars leader.
According to the corporation, Rhonda Duffy has been named Chief Operating Officer (COO) and will oversee production, quality, and supply chain management. She has over 30 years of expertise in the pharmaceutical sector worldwide.
Dr. Sandeep Athalye, who has been Chief Medical Officer of Biocon Biologics for over 6 years, has been promoted to Chief Development Officer, where he will oversee CMC, Clinical Development, and Medical and Regulatory Affairs.
As Global Head of Business Development, David Gibson joins the firm from GlaxoSmithKline (GSK) to oversee all licensing, strategic partnership, and business development efforts.
Stephanie Wasco joins as Head of Communications – Advanced Markets, where she will be responsible for Corporate and Marketing Communications as well as Product Branding in Advanced Markets such as the United States and Europe.
In addition to the aforementioned important executive hires, the Company has hired worldwide professionals in a variety of disciplines, including Manufacturing Science and Technology (MSAT), Clinical Development, Finance, Human Resources, Legal, and Compliance.
“These new additions to the leadership team bring rich, global experience that will help prepare the organization for the future and ensure a seamless integration of the recently acquired global biosimilars business from Viatris,” said Shreehas Tambe, CEO and Managing Director of Biocon Biologics. This will help us to improve performance, dependability, and sustainability while meeting our mission to supply high-quality, inexpensive biosimilars to millions of patients worldwide.”